292 related articles for article (PubMed ID: 4189571)
1. Suppressibility of thyroid function during treatment with antithyroid drugs in Grave's disease.
Wils JA; Kloppenborg PW
J Clin Endocrinol Metab; 1970 Mar; 30(3):406-7. PubMed ID: 4189571
[No Abstract] [Full Text] [Related]
2. Responsiveness to thyrotropin releasing hormone and thyroid suppressibility in Graves' disease patients remaining in remission after antithyroid drug therapy.
Rajatanavin R; Mahatumarat P; Poochanugool L; Kumpolpunth S; Himathongkam T
J Med Assoc Thai; 1981 Jan; 64(1):11-8. PubMed ID: 6163837
[No Abstract] [Full Text] [Related]
3. [Thyroid function and the state of the hypothalamus-hypophysis-thyroid in patients with diffuse toxic goiter after treatment].
Aliakparova ASh
Sov Med; 1973 Dec; 36(12):45-8. PubMed ID: 4130665
[No Abstract] [Full Text] [Related]
4. Thyroid suppressibility and long-acting thyroid stimulator in thyrotoxicosis.
Silverstein GE; Burke G
Arch Intern Med; 1970 Oct; 126(4):615-20. PubMed ID: 4097002
[No Abstract] [Full Text] [Related]
5. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the long-term results of antithyroid drug therapy for thyrotoxicosis.
Alexander WD; McLarty DG; Robertson J; Shimmins J; Brownlie BE; Harden RM; Patel AR
J Clin Endocrinol Metab; 1970 Apr; 30(4):540-3. PubMed ID: 4190916
[No Abstract] [Full Text] [Related]
8. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
Buerklin EM; Schimmel M; Utiger RD
J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
[TBL] [Abstract][Full Text] [Related]
9. Thyroid gland in Graves' disease: victim or culprit?
Chopra IJ; Solomon DH; Johnson DE; Chopra U
Metabolism; 1970 Oct; 19(10):760-72. PubMed ID: 5535910
[No Abstract] [Full Text] [Related]
10. Clinical efficacy of Yingliu mixture combined with metimazole for treating diffuse goitre with hyperthyroidism and its impact on related cytokines.
Yang H; Cong Y; Wu T; Tang H; Ma M; Zeng J; Zhang W; Lian Z; Yang X
Pharm Biol; 2017 Dec; 55(1):258-263. PubMed ID: 27927064
[TBL] [Abstract][Full Text] [Related]
11. Thyrotrophin response to thyrotrophin-releasing hormone in ophthalmic Graves' disease: correlation with other aspects of thyroid function, thyroid suppressibility and activity of eye signs.
Ormston BJ; Alexander L; Evered DC; Clark F; Bird T; Appleton D; Hall R
Clin Endocrinol (Oxf); 1973 Oct; 2(4):369-76. PubMed ID: 4128973
[No Abstract] [Full Text] [Related]
12. A thyroid suppression test using a single dose of L-thyroxine.
Wallack MS; Adelberg HM; Nicoloff JT
N Engl J Med; 1970 Aug; 283(8):402-5. PubMed ID: 4193842
[No Abstract] [Full Text] [Related]
13. Thyrostatic drugs act through modulation of thyroid cell activity to induce remissions in Graves' disease.
Volpé R; Karlsson A; Jansson R; Dahlberg PA
Acta Endocrinol Suppl (Copenh); 1987; 281():305-11. PubMed ID: 2441553
[No Abstract] [Full Text] [Related]
14. Antithyroid drugs.
Cooper DS
N Engl J Med; 2005 Mar; 352(9):905-17. PubMed ID: 15745981
[No Abstract] [Full Text] [Related]
15. Pituitary-thyroid feedback regulation in patients with Graves' disease during antithyroid drug therapy.
Yamada T; Takasu N; Sato A; Aizawa T; Koizumi Y
J Clin Endocrinol Metab; 1982 Jan; 54(1):83-8. PubMed ID: 6798061
[TBL] [Abstract][Full Text] [Related]
16. [Normalization of the functional regulation of the thyroid as a criterion of the remission of diffuse toxic goiter following antithyroid treatment].
Khelds AO
Probl Endokrinol (Mosk); 1986; 32(4):11-4. PubMed ID: 2429297
[TBL] [Abstract][Full Text] [Related]
17. Thyroid suppression test and outcome of hyperthyroidism treated with antithyroid drugs and triiodothyronine.
Yamamoto M; Igarashi T; Kimura S; Tsukamoto S; Togawa K; Ogata E
J Clin Endocrinol Metab; 1979 Jan; 48(1):72-7. PubMed ID: 581766
[No Abstract] [Full Text] [Related]
18. [Clinical significance of determination of early thyroidal 131-I uptake rate--relationship with 24-hour 131-I uptake rate].
Nagataki S; Uchimura H; Irie M; Tsushima T; Masuyama H
Horumon To Rinsho; 1972 Feb; 20(2):107-14. PubMed ID: 4112484
[No Abstract] [Full Text] [Related]
19. [The inhibition test of thyroid function with triiodothyronine in hyperthyroid patients under medical therapy: comparison of the values obtained from measures of "early" uptake and in the organic phase].
Valentini F; Reschini E; Lodeserto A; Vivarelli S; Miedico D
Folia Endocrinol; 1968 Aug; 21(4):396-403. PubMed ID: 4185869
[No Abstract] [Full Text] [Related]
20. [Evolution of iodine uptake, PBI-131, PBI-127 and clinical symptoms following administration of triiodothyronine to subjects with hyperthyroidism caused by diffuse thyroid hyperplasia. Role of the lymphatic system and LATS in the effect of Graves disease stimulation].
Mahaux JE; Chamla-Soumenkof J; Nagel M; Levin S
Ann Endocrinol (Paris); 1968; 29(4):483-95. PubMed ID: 5756676
[No Abstract] [Full Text] [Related]
[Next] [New Search]
